CAS 1185888-32-7
:N-[[1-(Cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-3-methyl-L-valin methylester
- N-[[1-(Cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-3-methyl-L-valine methyl ester
- L-Valine, N-[[1-(cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-3-methyl-, methyl ester
MDMB-CHMINACA
CAS:Kontrolliertes ProduktApplications MDMB-CHMINACA is a synthetic cannabinoid with potential neurochemical effects at the CB1 receptor. Synthetic Cannabinoids
References Banister, S. ET AL.: ACS Chem. Neurosci., 7, 1241 (2016);Formel:C22H31N3O3Farbe und Form:NeatMolekulargewicht:385.5MDMB-CHMINACA-d11
CAS:Kontrolliertes ProduktFormel:C22D11H20N3O3Farbe und Form:NeatMolekulargewicht:396.568MDMB-CHMINACA
CAS:Kontrolliertes ProduktMDMB-CHMINACA is a synthetic cannabinoid that has been shown to have potent antagonistic effects at the CB2 receptor, which may be due to its ability to inhibit lipid metabolism in human liver cells. MDMB-CHMINACA has also been shown to have high binding affinities for both the CB1 and CB2 receptors and is metabolized through a number of metabolic transformations, including hydrolysis by esterases or glucuronidases, oxidation by cytochrome P450 enzymes, reduction by glutathione reductase, or conjugation with glucuronic acid. The compound's structural analysis was validated using LC-MS/MS methods. Urine samples from individuals who had consumed MDMB-CHMINACA were analyzed using this method and showed that the compound could not be detected in urine samples with concentrations below 2 μg/mL.
Reinheit:Min. 95%

